Barbara Weber is president and CEO of Tango Therapeutics, a biotechnology company she began building shortly after joining Third Rock Ventures in March 2015. Tango is a precision oncology company focused on identifying novel targets and developing new drugs based on the genetic principle of synthetic lethality. Barbara has led the company from its inception as a Series A startup funded by Third Rock Ventures, now a publicly-traded clinical stage company.  In addition to Tango Therapeutics and Parabilis Medicines, Barbara currently serves on the board of directors of Revolution Medicines and OPY Acquisition Corp I.

Prior to joining Third Rock Ventures, Barbara was senior vice president and global head, oncology translational medicine at Novartis from 2009 to 2015 and vice president, oncology discovery and translational medicine at GlaxoSmithKline from 2005 to 2009. Prior to joining the pharmaceutical industry, Barbara was professor of medicine and genetics at The University of Pennsylvania, leading a clinical and translational research program in cancer genetics.

Barbara is an elected member of the American Association of Physicians and the American Society for Clinical Investigation, of which she served as president in 2005. Barbara also has served on the board of directors of both ASCO and AACR. After earning her B.S. degree in chemistry from the University of Washington, Barbara graduated from the University of Washington School of Medicine. She completed her residency in internal medicine at Yale University and a fellowship in medical oncology at the Dana-Farber Cancer Institute.